Prader-Willi Syndrome

Rare Disease·MeSH: Prader-Willi Syndrome

Prevalence

0.5 / 100K

11 drugs in development·8 companies·11 clinical trials

Drug Pipeline by Phase

Approved(1)

Drug	Company
vykat xr	SOLENO THERAPEUTICS INC (SLNO)

Phase 3(3)

Drug	Company
Carbetocin	ACADIA PHARMACEUTICALS INC (ACAD)
pitolisant	MBX Biosciences, Inc. (MBX)
WAKIX (pitolisant) - Prader-Willi Syndrome (PWS)	Harmony Biosciences Holdings, Inc. (HRMY)

Phase 2(3)

Drug	Company
BMB-101	BRIGHT MINDS BIOSCIENCES INC. (DRUG)
sepranolone	RELMADA THERAPEUTICS, INC. (RLMD)
Setmelanotide	RHYTHM PHARMACEUTICALS, INC. (RYTM)

Preclinical(2)

Drug	Company
HBS-102	Harmony Biosciences Holdings, Inc. (HRMY)
rad011	Radius Health, Inc. (RDUS)

BLA Filed(1)

Drug	Company
dccr	SOLENO THERAPEUTICS INC (SLNO)

Phase 1/Phase 2(1)

Drug	Company
RM-718	RHYTHM PHARMACEUTICALS, INC. (RYTM)

BioSniper tracks 11 drugs in development for Prader-Willi Syndrome across 8 companies.

There are 11 clinical trials targeting Prader-Willi Syndrome tracked by BioSniper.

The estimated prevalence of Prader-Willi Syndrome is approximately 0.5 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.